Focus on Anticoagulation Care

Back to articles

New data support apixaban over rivaroxaban for newly diagnosed VTE

KEY POINT

Use of apixaban (Eliquis—Bristol–Myers Squibb, Pfizer) appears to be more effective than rivaroxaban (Xarelto—Janssen) for prevention of recurrent venous thromboembolism (VTE) with a decreased risk of major bleeding events, according to results of a retrospective, observational study published in The Lancet Haematology.